DB2114930: A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD.

Trial Profile

DB2114930: A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Umeclidinium/vilanterol (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms Advair v Zephyr
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Feb 2014 According to ClinicalTrials.gov record, status changed from recruiting to completed.
    • 29 Mar 2013 Planned number of patients changed from 706 to 710 as reported by ClinicalTrials.gov.
    • 22 Mar 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01817764).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top